The Antitrust Prescription Archive

In the latest article for The Antritrust Prescription, Edgeworth Managing Principal Dr. Ashley Zhou examines recent enforcement concerning the listing of patents in the FDA's Orange Book and potential economic implications of new enforcement efforts.

In this new article for The Antitrust Prescription, our pharmaceutical economics team discusses Amgen’s proposed acquisition of Horizon and the FTC’s broader approach to challenging conduct under Section 5 of the FTC Act. 

In this edition of The Antitrust Prescription, our Pharmaceutical Economics team discusses Merck and Glenmark's  settlements with direct purchasers, end payors, and retailers worth over a combined $600 million. 

In this article, Dr. George Korenko and Dr. Tram Nguyen discuss a brief history of the numerosity standards and the potential implications of recent decisions in pharmaceutical antitrust matters.